Evidence map›Paper›PMID 41289009›Full record

ArticleThe Journal of clinical investigation2026

Functional consequence of pathogenic GABRA3 variants determines whether X-linked inheritance is dominant or recessive.

Katrine M Johannesen, Khaing Phyu Aung, Vivian Wy Liao, Nathan Absalom, Han C Chua, Xue N Gan, Miaomiao Mao, Chaseley E McKenzie, Hian M Lee, Sebastian Ortiz and 41 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors.

Katrine M JohannesenDepartment of Epilepsy Genetics and Personalized Treatment, Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark.
Khaing Phyu AungThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Vivian Wy LiaoSchool of Medical Sciences, Faculty of Medicine and Health, Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.
Nathan AbsalomSchool of Medical Sciences, Faculty of Medicine and Health, Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.
Han C ChuaSydney Pharmacy School, Faculty of Medicine and Health and Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
Xue N GanThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Miaomiao MaoThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Chaseley E McKenzieThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Hian M LeeThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Sebastian OrtizDepartment of Epilepsy Genetics and Personalized Treatment, Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark.
Rebecca C SpillmannDepartment of Pediatrics, Division of Medical Genetics, and.
Vandana ShashiDepartment of Pediatrics, Division of Medical Genetics, and.
Rodney A RadtkeDepartment of Neurology, Duke University School of Medicine, Durham, North Carolina, USA.
Ghayda M MirzaaDepartment of Laboratory Medicine and Pathology and.
P Anne WeisnerDepartment of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.
Josue Flores DaboubDepartment of Pediatrics, Genetics Division, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Caroline HagedornDepartment of Pediatrics, Genetics Division, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Pinar Bayrak-ToydemirDepartment of Pathology, University of Utah, Salt Lake City, Utah, USA.
Desiree DeMilleARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA.
Jian ZhaoDepartment of Pathology, University of Utah, Salt Lake City, Utah, USA.
Nandita BajajDepartment of Neuropediatrics, Christian Children's Hospital Osnabrück, Osnabrück, Germany.
Yline CapriDepartment of Genetics, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris Nord, University of Paris, Paris, France.
Boris KerenDepartment of Medical Genetics, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.
Miriam SchmidtsCenter for Pediatrics and Adolescent Medicine, Freiburg University Hospital, Faculty of Medicine, and.
Ingrid Mbh van de LaarDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Marjon A van SlegtenhorstDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Rafal PloskiDepartment of Medical Genetics, Warsaw Medical University, Warsaw, Poland.
Marta BogotkoProfessor Jan Bogdanowicz Children's Hospital, Warsaw, Poland.
Danielle K BourqueDivision of Metabolics and Newborn Screening, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada.
Ebba AlkhunaiziDivision of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
Lauren ChadDivision of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
Nada QuerciaDivision of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
Houda ElloumiGeneDx, Gaithersburg, Maryland, USA.
Ingrid M WentzensenGeneDx, Gaithersburg, Maryland, USA.
Michael C KruerPediatric Movement Disorders Program, Division of Pediatric Neurology, Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Pritha BisaradPediatric Movement Disorders Program, Division of Pediatric Neurology, Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Carolina I Galaz-MontoyaPediatric Movement Disorders Program, Division of Pediatric Neurology, Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Violeta RusuDepartment of Human Genetics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Dominique BraunDepartment of Human Genetics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Katie AngioneDepartment of Child Neurology, Children's Hospital Colorado, Aurora, Colorado, USA.
Jessica C WinDepartment of Neurology, Riley Children's Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Camilo Espinosa-JovelEpilepsy Program, Instituto Roosevelt, Bogotá, Colombia.
Pia ZacherCenter for Adults with Disability (MZEB), Epilepsy Center Kleinwachau, Radeberg, Germany.
Konrad PlatzerInstitute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
Samuel F BerkovicDepartment of Medicine, Epilepsy Research Centre, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
Ingrid E SchefferThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Mary ChebibSchool of Medical Sciences, Faculty of Medicine and Health, Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.
Guido RubboliDepartment of Epilepsy Genetics and Personalized Treatment, Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark.
Rikke S MøllerDepartment of Epilepsy Genetics and Personalized Treatment, Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark.
Christopher A ReidThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Philip K AhringSchool of Medical Sciences, Faculty of Medicine and Health, Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.

Funding

An integrated and diverse genomic medicine program for undiagnosed diseasesU01HG007672 · NHGRI · DUKE UNIVERSITY · PI SHASHI, VANDANA · 2014 to 2022
$13.4M
An integrated and diverse genomic medicine program for undiagnosed diseasesU01NS134350 · NINDS · DUKE UNIVERSITY · PI VANDANA SHASHI · 2023 to 2026
$3.6M
Genomic analysis of the Multiplex, Autozygous Populations in Cerebral Palsy (MAP CP) cohort: a focused approach to a complex diseaseR01NS127108 · NINDS · UNIVERSITY OF ARIZONA · PI Michael C Kruer · 2023 to 2026
$2.6M
NHGRI NIH HHS U01 HG007672NINDS NIH HHS R01 NS127108NINDS NIH HHS U01 NS134350
6 · The paper itself

Abstract

Disorders of GABRA3, the only epilepsy-associated GABAA receptor subunit gene on the X chromosome, have eluded clinical clarity due to ambiguous inheritance patterns and variable phenotypes. The long-standing assumption that all pathogenic variants cause loss of function further obscured genotype-phenotype relationships and hindered progress. Here, we curated a cohort of individuals with a GABRA3 variant, integrating deep phenotyping, genotyping, family history, and electrophysiology with a targeted mouse model. Among 43 individuals with 19 GABRA3 variants, functional analyses revealed gain- and loss-of-function effects, each linked to distinct clinical profiles. Gain-of-function variants were associated with severe, treatment-resistant epilepsy and profound intellectual disability, disproportionately affecting males, who were often nonambulant and had cortical visual impairment. Loss-of-function variants produced milder phenotypes, with epilepsy rarely observed; affected males showed behavioral issues and language delay, while females were unaffected carriers. Our gain-of-function (Gabra3Q242L/+) mouse model mirrored these sex-specific differences, showing increased seizure susceptibility, early death, and marked cortical hyperexcitability. These insights resolve longstanding uncertainties surrounding GABRA3 and redefine how X-linked disorders are interpreted. They demonstrate that it is the functional impact of a variant, not its mere presence, that determines whether a condition manifests dominantly or recessively. This distinction carries important implications for genetic counseling, precision medicine, and the broader interpretation of X-linked neurodevelopmental disorders.

Indexed as

Chromosomes, Human, XEpilepsyGain of Function MutationGenes, DominantGenes, RecessiveGenes, X-LinkedGenetic Diseases, X-LinkedIntellectual DisabilityReceptors, GABA-AAnimalsFemaleHumansMaleMiceGABRA3 protein, humanReceptors, GABA-AEpilepsyGenetic diseasesGeneticsIntellectual disabilityNeuroscience

Identifiers

PMID41289009
PMCPMC12807467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.